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Abstract Chemical synthesis of Agouti proteins ^ Agouti and
Agouti-related proteins ^ is complicated by their large size and
by multiple cysteine residues located in the carboxyl terminal
regions. Three human Agouti-related protein (AGRP) fragments,
two of which correspond to a proposed endoprotease cleavage site
between amino acids 82 and 83, were synthesized and tested for
anti-melanotropic activity using Xenopus laevis dermal melano-
phores. Amino-terminal fragments AGRP(25^51) and (54^82)
were devoid of significant antagonist activity, whereas the
amidated carboxyl-terminal AGRP fragment (83^132)-NH2
was potently active with an inhibitory equilibrium dissociation
constant (Ki) of 0.7 nM. The ability to synthesize functionally
active AGRP should help unravel its role in the central nervous
system and its unusual properties with respect to interaction with
the melanocortin family of G-protein coupled receptors.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The Agouti protein is perhaps best known for its modula-
tion of coat color in mice. Normally expressed in skin cells,
the protein e¡ects this function by regulating eumelanin pig-
ment synthesis via its antagonism of melanocortin subtype-1
(MC1) receptors. Ectopically expressed, Agouti can lead to a
condition characterized by yellow coat color, where the nor-
mal pigmentation response to K-melanocyte-stimulating hor-
mone (K-MSH) in dermal papilla cells of the hair follicle has
been disrupted [1^6]. Paradoxically, mutant alleles of the
Agouti gene a¡ect not just processes of the skin but also
broadly based characteristics such as obesity and hyperinsuli-
nemia. A clue to the puzzle of such widespread e¡ects may lie
in a recently identi¢ed relative of Agouti, called Agouti-re-
lated protein (AGRP), which appears to be expressed primar-
ily in the adrenal gland and the hypothalamus [1,2]. AGRP
seems to play its role in the nervous system by inhibiting MC4
receptors, which are key players in energy homeostasis, food
intake and obesity, and the leptin hormonal pathway [1,3,4].
Unraveling the molecular speci¢cs of AGRP’s activity may
suggest a means by which to treat malfunction in some of
these key physiological processes. Our strategy to achieve
such molecular level inquiry is to chemically synthesize a bio-
active fragment of the 132 amino acid parent human AGRP
molecule. This synthesis gives us access to a host of structural
and mechanistic studies of AGRP, while bypassing the poten-
tially laborious synthetic and puri¢cation procedures that ac-
company the recombinant expression systems currently used
to obtain AGRP [1,5].
While the structural features that determine potency and
receptor speci¢city of human Agouti and AGRP remain elu-
sive, the cysteine-rich carboxy terminus of each appears im-
portant for activity. Indeed, it is in this region that the pro-
teins are most strikingly similar, exhibiting better than 50%
identity for portions of their carboxyl halves. (Global se-
quence identity across their entire 132 amino acids is 30%.)
Site-directed modi¢cation of four residues in this domain of
mouse Agouti ^ Val(83), Arg(85), Pro(86) and Pro(89) ^ re-
duced binding of iodinated [Nle4,D-Phe7]-K-MSH to MC re-
ceptors [7], suggesting a key role for the carboxy terminus in
Agouti’s biological activity. Ollman et al. [1] have demon-
strated analogous results for AGRP; partially puri¢ed frac-
tions of AGRP containing C-terminal fragments (residues 69^
132 or 71^132) antagonized K-MSH induced pigment disper-
sion in Xenopus melanophores with a potency similar to or
slightly greater than fractions containing longer fragments
(residues 24^132, 46^132, 48^132, or 50^132). It may well be
that proteolytic processing of these proteins occurs in vivo.
Based on analogy to the processing pattern of atrial-natriu-
retic factor [8,9], we propose that Pro(81)-Arg(82) of human
AGRP, and Pro(85)-Arg(86) of human Agouti, may act as
cleavage sites for the generation of biologically active protein
fragments. We therefore synthesized a fragment correspond-
ing to residues 83^132 of the AGRP protein, mimicking the
purported proteolytic processing; peptides corresponding to
more amino terminal parts of AGRP (residues 25^51 and
54^82) were generated to serve as controls.
Production of AGRP by any means, chemical or biological,
is complicated by the protein’s numerous cysteine residues.
AGRP bears 11 cysteines in total, 10 of which are con¢ned
to the carboxyl half of the molecule; the potential for disul¢de
mismatches is large. Assignments of disul¢de connectivities in
the native protein are yet to be made. The task is complicated
by the sheer number of cysteines and by the laboriousness of
procedures currently employed to obtain puri¢ed protein.
Some hints may be derived from the observation that cysteine
residues found in Agouti, and therefore AGRP, lie in homol-
ogous positions to those found in g-conotoxin GVIA, the N-
type calcium channel antagonist isolated from Conus geogra-
phus [10]. We have employed a biological assay using Xenopus
melanophores to test the activity of synthetic fragments, pos-
iting that the successful chemical synthesis of an active frag-
ment implies that its folding pattern mimics the normal con-
formation. We suggest that chemical synthesis o¡ers reliable
means to manipulate protein structure and to obtain the ma-
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terial so crucial to the determination of endogenous disul¢de
arrangements and biological mechanism.
2. Materials and methods
2.1. Protein synthesis and puri¢cation
Protein fragments of human AGRP consisting of residues (25^51)
with the sequence LAPMEGIRRPDQALLPELPGLGLRAPL, (54^
82) with the sequence TTAEQAEEDLLQEAQALAEVLDLQ-
DREPR, and the amidated form of (83^132) with the sequence
SSRRCVRLHESCLGQQVPCCDPCATCYCRFFNAFCYCRKLG-
TAMNPCSRT-NH2 were synthesized on an Applied Biosystems
433A automated peptide synthesizer (Foster City, CA), using hydrox-
ymethyl or para-methyl benzylhydrylamine resin as the solid support
and standard solid-phase Fmoc methods. N-terminal Fmoc amino
acids were deprotected with piperidine in dimethylformamide (20%,
v/v) and coupled using o-benzotriazole-N,N,NP,NP-tetramethyluro-
nium hexa£uorophosphate in 1-hydroxybenzotriazole (1:1 molar
equivalents, in 5 molar excess). Protein fragments were cleaved from
resin with hydrogen £uoride containing anisole (10%, v/v) and di-
methyl sul¢de (1%, v/v) for 45 min at 0‡C, washed with diethylether,
and extracted with water/acetonitrile (50%, v/v). AGRP-(83^132)-NH2
fragments were cyclized in an acetonitrile/H2O solution, adjusted to
pH 8.5 with ammonium hydroxide, for 72 h, and extracted with Bio-
Rex 70 cation exchange resin for 24 h. The Bio-Rex resin was then
rinsed with H2O, cyclized protein eluted from the resin with 50%
glacial acetic acid in H2O (v/v), and major fractions analyzed by Pauly
spray. Major fractions were puri¢ed by HPLC using a Vydac C-18
column (5 micron pore size) over a standard linear gradient of 100%
H2O (0.1% tri£uoroacetic acid) to 60% acetonitrile (0.1% tri£uoro-
acetic acid). Samples were then roto-evaporated, lyophilized, and an-
alyzed using matrix assisted laser desorption ionization-time of £ight
(MALDI-TOF) and electrospray mass spectrometry.
2.2. Testing synthetic AGRP fragments for functional antimelanotropic
activity
Synthetic human AGRP fragments were assayed for antagonist
activity using Xenopus laevis dermal melanophore cell preparations
as described previously [11,12]. Cultured melanophores can translo-
cate cytoplasmic pigment vesicles in response to hormonal stimulation
by K-MSH, norepinephrine, vasotocin, pituitary adenylylcyclase acti-
vating peptide (PACAP), and serotonin. These compounds cause pig-
ment dispersion and cell darkening. Pigment aggregation and cell
lightening can be stimulated by melatonin. Melanophore responses
were determined by measuring absorbance (OD) ratios taken through
a monolayer of cells using a FisherBiotec BT2000 Microplate Reader
(Pittsburgh, PA). Absorbance was measured before and after a 90-min
exposure to test peptides and then expressed as percent of initial
absorbance. Measurements were taken after 60 min pretreatment
with 10 nM melatonin to initiate readings from an aggregated state.
3. Results
3.1. Protein synthesis and mass spectra analysis
Three preparatory HPLC separations of synthetic extracts
yielded protein fragments which were 99% pure by analytical
HPLC (Fig. 1). MALDI-TOF mass spectrometric analysis of
the linear AGRP fragments gave a molecular mass of 2894.5
Da for (25^51) and 3282.5 Da for (54^82), both of which
correspond to expected theoretical values. The molecular
mass of cyclized AGRP(83^132)-NH2 as determined by
MALDI-TOF and electrospray mass spectra was 5678.04
(S.E. 0.1%) and 5677.0 (S.E. 0.01%) Da, respectively (Fig.
1). These values are consistent with the calculated theoretical
FEBS 20253 25-5-98
C
Fig. 1. A: Analytical HPLC of the puri¢ed fraction of AGRP-(83^
132)-NH2 used in mass spectrometric and in vitro testing. Tracing is
for a linear gradient from 0% Bu¡er B to 100% Bu¡er B/40 min,
where Bu¡er A = 100% water/0.1% tri£uoroacidic acid (v/v) and
Bu¡er B = 60% acetonitrile/0.1% tri£uoroacidic acid (v/v). Flow rate
was set at 1 ml/min and the detector set to 220 nm. Sample injec-
tion volume was 0.02 ml onto a 27.5U0.5 cm Vydac C-18 column
with a 5-W pore size. B: Electrospray mass spectrum of AGRP-(83^
132)-NH2 reveals one major peak at 5677.0 Da, which corresponds
to the expected theoretical mass of a fully cyclized protein. C:
MALDI-TOF mass spectrometric analysis was used to con¢rm that
the minor peaks in the electrospray analysis were due to multiply
charged ions or fragment ions. The ¢nal mass was calculated by
subtracting one proton mass unit from the indicated value of
5679.04 Da.
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mass of 5676.7 Da for protein containing a full complement
of ¢ve disul¢de bonds.
3.2. Antagonist activity of AGRP fragments
Synthetic AGRP-(83^132)-NH2 produced a dose-dependent
suppression of K-MSH-induced dispersion of pigment in mel-
anophore cells (Fig. 2). Under the same experimental condi-
tions, AGRP(25^51) and AGRP(54^82) were inactive. The
inhibitory equilibrium dissociation constant (Ki) of human
AGRP(83^132)-NH2, as determined by Schild regression
analysis, was 0.7 (S.E. 0.4) nM (Fig. 3), which is comparable
to Kd values reported for AGRP and Agouti protein puri¢ed
by recombinant means [1,6]. Each of the three protein frag-
ments had no ‘agonist like’ activity in melanophore cells.
When applied to melanophores in the absence of K-MSH,
the peptides did not cause pigment dispersion in the presence
of 10 nM melatonin (data not shown). The speci¢city of
AGRP for MC receptor-mediated response was tested by ex-
amining AGRP(83^132)-NH2 for interaction with other li-
gands known to induce pigment dispersion. AGRP(83^132)-
NH2 (30 nM) had no e¡ect on concentration-response curves
evoked with norepinephrine, serotonin, PACAP-27, and
[Arg8]-vasotocin, indicating that antagonism is selectively di-
rected towards responses initiated by K-MSH stimulation of
MC receptors.
4. Discussion
Our results demonstrate that a synthetic fragment of human
AGRP based on the amino acid sequence (83^132) can po-
tently antagonize MC receptor function in Xenopus melano-
phores; the amino-terminal fragments (25^51) and (54^83) are
inactive as antagonists. Although it is not known what enzy-
matic processes shape AGRP in vivo, we have surmised by
analogy to atrial-natriuretic peptide, that AGRP may contain
an endoprotease cleavage site between amino acids 82 and 83.
This hypothesis is strengthened by our ¢nding that the ami-
dated carboxyl protein fragment that corresponds to this pro-
posed cleavage site, i.e. AGRP(83^132)-NH2, is fully active
and has a Ki similar to, or perhaps even less than, values
reported for longer fragments containing greater portions of
the amino-terminus [1]. Thus, it appears that the cysteine-rich
carboxyl-terminal region of AGRP, the region with highest
homology to Agouti protein, accounts for all of its anti-mel-
anotropic activity in melanophores. We are currently in the
process of producing antibodies to AGRP(83^132), and this
may help address whether AGRP fragments which correspond
to this cleavage site can actually be found in vivo.
Electrospray mass spectrometry is an accurate method of
determining protein molecular mass and purity, but proteins
can produce multiply charged ions and fragment ions. This
problem is accentuated with AGRP(83^132)-NH2 because of
its numerous disul¢de sites. Although the major peak in the
electrospray mass spectrum was 5677.0 Da, it also contained a
number of minor peaks which were di⁄cult to interpret. The
major peak was consistent with protein containing ¢ve disul-
¢de bonds; which was expected since cyclization reactions
usually proceed to completion. To better resolve the origin
of the minor peaks in the electrospray analysis, we retested
AGRP(83^132)-NH2 using MALDI-TOF mass spectrometry,
a procedure less prone to fragmentation. The MALDI-TOF
mass spectrogram contained only one major peak and con-
¢rmed our suspicion that minor peaks in the electrospray
procedure were likely due to fragmentation. Thus, an
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Fig. 3. A: Synthetic APR-(83^132)-NH2 caused a 100-fold shift in the concentration-response curve to K-MSH. The EC50 of K-MSH was 0.16
(S.E. 0.03) nM in the absence (a), and 19 (S.E. 5) nM in the presence (b), of 100 nM AGRP-(83^132)-NH2. Each symbol represents the mean
and standard deviation of four independent measurements. B: Schild regression analysis indicates the pKi of synthetic AGRP-(83^132)-NH2 is
9.18 (S.E. 0.25). The slope of the regression is 1.3 (S.E. 0.1) and the correlation coe⁄cient 0.96. Broken lines indicate the 95% con¢dence inter-
val.
Fig. 2. AGRP-(83^132)-NH2 (a) potently inhibits activation of pig-
ment dispersion in melanophore cells by 300 pM K-MSH with an
IC50 of 1.7 (S.E. 1.5) nM. N-terminal fragments AGRP-(25^51) (O)
and AGRP (54^82) (R) were inactive or had IC50 values in excess
of 10 WM. Each symbol represents the mean and standard deviation
of four independent measurements.
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AGRP(83^132)-NH2 structure containing a full complement
of disul¢de bonds appears to account for the biological activ-
ity observed in Xenopus melanophores.
The arrangement of disul¢de bonds in AGRP contributes
to the protein’s tertiary structure. Our ability to synthesize
biologically active molecules of AGRP chemically will make
the task of resolving these arrangements easier since disul¢de
bonds can now be assessed by systematically altering and re-
arranging protein structures without the need to rely on more
limiting and time consuming recombinant expression systems.
Despite current uncertainties about the pattern of disul¢de
bonding within AGRP, it is interesting to note that in vitro
formation of biologically active structures appears to proceed
spontaneously in the absence of the larger precursor protein.
Thus, the carboxyl-terminal region of AGRP, and possibly
Agouti protein as well, appear to contain all the necessary
secondary structure needed for proper bond formation and
folding into bioactive molecules.
As a selective and non-competitive inhibitor of MC4 recep-
tors in humans, AGRP likely regulates some of the crucial
physiological processes mediated by these receptors, including
energy homeostasis and food intake. Structural studies of our
chemically synthesized AGRP fragments may clarify the role
this protein plays in the body. Further, structural insights
gained from such research may facilitate the development of
even more potent and selective MC receptor antagonists ^
both peptide and peptoid in nature. We hope that the ability
to synthesize active fragments of AGRP and, we anticipate,
Agouti as well will eventually elucidate their participation in
obesity and diabetes [2,13], leading to better treatments for
these conditions.
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